Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862570 | 1.00 | RAB9A (0.70) | RAB9ANPC1KMT2AMAPTGFER | |
| SCHEMBL2599799 | 1.00 | RAB9A (0.70) | RAB9ANPC1KMT2AMAPTGFER | |
| Hydrochloric Acid SCHEMBL7329333 | 0.98 | RAB9A (0.68) | RAB9ANPC1KMT2AMAPTGFER | |
| Ammonia Solution, Strong SCHEMBL8218102 | 0.98 | RAB9A (0.68) | RAB9ANPC1KMT2AMAPTGFER | |
| Hydrochloric Acid SCHEMBL7329327 | 0.98 | RAB9A (0.68) | RAB9ANPC1KMT2AMAPTGFER | |
| SCHEMBL6076687 | 0.83 | ALDH1A1 (0.61) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL6076692 | 0.83 | ALDH1A1 (0.61) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL19439618 | 0.81 | ALDH1A1 (0.59) | RAB9ANPC1KMT2AMAPTALDH1A1 | |
| SCHEMBL13934092 | 0.81 | CA2 (0.88) | RAB9ANPC1MAPTALDH1A1CA1 | |
| SCHEMBL31490543 | 0.81 | KDM4E (0.53) | RAB9ANPC1KMT2AMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907127-B2 | Preparation method of 4-aminomethylbenzoic acid | NAF CO LTD (KR) | 2014-12-09 | — | — | US | claimed |
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | disclosed |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2025-12-02 | — | — | US | disclosed |
| US-20250109095-A1 | METHOD FOR PREPARING OXIME DERIVATIVE | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-04-03 | — | — | US | disclosed |
| EP-4520326-A2 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-3924340-B1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| CN-118955486-A | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113474334-B | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117794924-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230355590-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | NISSAN CHEMICAL CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-6107458-A | FUNGICIDE WHICH IS BETA-1,3-GLYCAN SYNTHASE INHIBITOR; FOR PROPHYLAXIS AND TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS LIKE PNEUMONIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1168675-A | Novel compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5338749-A | Treating rheumatic or arthritic disorders | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355590-A1 | ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE | HDAC7, ACHE, BRDT | RAB9A 1269/4885NPC1 3008/4885KMT2A 342/4885 |
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, ABL1, DSTYK | RAB9A 1762/4885NPC1 3212/4885KMT2A 855/4885 |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | KIT, TNNI3K, CILK1 | RAB9A 2229/4885NPC1 2038/4885KMT2A 1369/4885 |
| US-20250109095-A1 | METHOD FOR PREPARING OXIME DERIVATIVE | NOS2, NOS1, NOS3 | RAB9A 4013/4885NPC1 4600/4885KMT2A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.